Erasca (ERAS) vs Kiniksa Pharmaceuticals International (KNSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Erasca (ERAS) has outperformed Kiniksa Pharmaceuticals International (KNSA) over the past year, gaining 469.4% versus a gain of 104.5%. Over five years, KNSA leads with a +580.9% price change compared with -20.7% for ERAS. Kiniksa Pharmaceuticals International is the larger company by market cap ($6.14 billion vs $5.41 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ERAS | KNSA |
|---|---|---|
| Share price | $15.46 | $78.75 |
| Market cap | $5.41B | $6.14B |
| 1-day change | +9.49% | +1.01% |
| YTD return | +279.57% | +88.99% |
| 1-year return | +469.35% | +104.51% |
| 5-year return | -20.67% | +580.87% |
| P/E ratio (TTM) | — | 79.55 |
| Forward P/E | — | 48.69 |
| EPS (TTM) | $-0.95 | $0.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $677.56M |
| Revenue growth (YoY) | — | +60.09% |
| Net income (latest FY) | $-124.55M | $59.01M |
| Gross margin | — | 88.54% |
| Operating margin | — | 11.40% |
| Net margin | — | 8.71% |
| 52-week high | $24.28 | $82.94 |
| 52-week low | $2.11 | $35.20 |
| Distance from 52-week high | -36.33% | -5.05% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +55.95% | +24.44% |
| Average volume | 4.28M | 578.96K |
| Shares outstanding | 349.76M | 48.29M |
| Employees | 103 | 366 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ERAS has outperformed KNSA by 364.8 percentage points over the past year.
About Erasca
ERAS stock →Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
About Kiniksa Pharmaceuticals International
KNSA stock →Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees
ERAS vs KNSA FAQ
Which is bigger, Erasca or Kiniksa Pharmaceuticals International?
Kiniksa Pharmaceuticals International (KNSA) is larger, with a market capitalization of $6.14B compared with $5.41B for Erasca (ERAS).
Which stock has performed better over the past year, ERAS or KNSA?
ERAS returned +469.35% over the past 12 months, compared with +104.51% for KNSA (price return, excluding dividends). Past performance does not predict future results.
Are Erasca and Kiniksa Pharmaceuticals International in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.